Cargando…
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide–cisplatin (EP) or docetaxel–cisp...
Autores principales: | Sen, Fatma, Tambas, Makbule, Ozkaya, Kubra, Guveli, Murat Emin, Ciftci, Rumeysa, Ozkan, Berker, Oral, Ethem Nezih, Saglam, Esra Kaytan, Saip, Pinar, Toker, Alper, Demir, Adalet, Firat, Pinar, Aydiner, Adnan, Eralp, Yesim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265838/ https://www.ncbi.nlm.nih.gov/pubmed/27472701 http://dx.doi.org/10.1097/MD.0000000000004280 |
Ejemplares similares
-
Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment
por: Aydiner, Adnan, et al.
Publicado: (2015) -
Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center
por: Ak, Naziye, et al.
Publicado: (2021) -
An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015) -
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2021) -
Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
por: Dogan, Izzet, et al.
Publicado: (2023)